Results 181 to 190 of about 52,225 (202)

Disruption of the Bcr-Abl/Hsp90 protein complex: a possible mechanism to inhibit Bcr-Abl-positive human leukemic blasts by novobiocin.

Leukemia, 2008
The Bcr-Abl fusion gene encodes for the p210(Bcr-Abl) or p185(Bcr-Abl) tyrosine kinase (TK) implicated in the pathogenesis of chronic myelogenous leukemia (CML) or acute lymphoblastic leukemia, respectively. Because Bcr-Abl TK is chaperoned by Hsp90 (90 kDa heat-shock protein), we investigated the effects of novobiocin (NB), an Hsp90 C-terminal ...
L X, Wu, J H, Xu, K Z, Zhang, Q, Lin, X W, Huang, C X, Wen, Y Z, Chen   +6 more
openaire   +1 more source

Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells.

Blood, 2000
J. T. Thiesing, Sayuri Ohno-Jones, K. Kolibaba, B. Druker   +3 more
semanticscholar   +1 more source

CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs.

Blood, 2000
G. Fang, C. N. Kim, C. L. Perkins, Nimmanapalli Ramadevi, E. Winton, S. Wittmann, K. Bhalla   +6 more
semanticscholar   +1 more source

Imatinib induces mitochondria‐dependent apoptosis of the Bcr‐Abl‐positive K562 cell line and its differentiation toward the erythroid lineage 1

The FASEB Journal, 2003
A. Jacquel, M. Herrant, L. Legros, N. Belhacéne, F. Luciano, G. Pagès, P. Hofman, P. Auberger   +7 more
semanticscholar   +1 more source

Bcl2 as a therapeutic target in BCR-ABL positive ALL

Klinische Pädiatrie, 2014
AK Elder, M Scherr, O Heidenreich, M Eder   +3 more
openaire   +1 more source

Differential gene expression patterns and interaction networks in BCR-ABL-positive and -negative adult acute lymphoblastic leukemias.

Journal of Clinical Oncology, 2006
D. Juric, Norman J. Lacayo, Meghan C. Ramsey, J. Racevskis, P. Wiernik, J. Rowe, A. Goldstone, P. O'dwyer, E. Paietta, B. Sikic   +9 more
semanticscholar   +1 more source

Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells

Leukemia, 2001
J. Topaly, W. Zeller, S. Fruehauf
semanticscholar   +1 more source

BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study

Lancet, The, 2002
Nikolas Von Bubnoff, Christian Peschel, Justus Duyster   +2 more
exaly  

Selective induction of apoptosis in Philadelphia chromosome-positive chronic myelogenous leukemia cells by an inhibitor of BCR–ABL tyrosine kinase, CGP 57148

Cell Death and Differentiation, 1998
Shingo Dan, Mikihiko Naito, Takashi Tsuruo   +2 more
exaly  

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance

Blood, 2007
Hagop Kantarjian, Francis J Giles, Kapil N Bhalla   +2 more
exaly